Product NDC: | 50242-060 |
Proprietary Name: | Avastin |
Non Proprietary Name: | bevacizumab |
Active Ingredient(s): | 100 mg/4mL & nbsp; bevacizumab |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 50242-060 |
Labeler Name: | Genentech, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA125085 |
Marketing Category: | BLA |
Start Marketing Date: | 20040226 |
Package NDC: | 50242-060-01 |
Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-060-01) > 4 mL in 1 VIAL, SINGLE-USE |
NDC Code | 50242-060-01 |
Proprietary Name | Avastin |
Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-060-01) > 4 mL in 1 VIAL, SINGLE-USE |
Product NDC | 50242-060 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | bevacizumab |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20040226 |
Marketing Category Name | BLA |
Labeler Name | Genentech, Inc. |
Substance Name | BEVACIZUMAB |
Strength Number | 100 |
Strength Unit | mg/4mL |
Pharmaceutical Classes | Vascular Endothelial Growth Factor Receptor Inhibitors [MoA],Vascular Endothelial Growth Factor-directed Antibody [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |